Showing 1221-1230 of 9359 results for "".
- WCD News: Tildrakizumab Improves Wellbeing of PsO Patientshttps://practicaldermatology.com/news/wcd-news-tildrakizumab-improves-wellbeing-of-pso-patients/2461848/Ilumetri (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis, according to research reported by Almirall, S.A. (ALM) at poster at the 25th World Congress of Dermatology in Singapore. Patients taking tildrakizumab achieved a wellbeing status sim…
- FDA Approves JUVÉDERM VOLUX XC for Jawline Definitionhttps://practicaldermatology.com/news/fda-approved-juvederm-volux-xc-for-jawline-definition/2461286/The U.S. FDA has given its nod to JUVÉDERM VOLUX XC for the improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition. "The approval of JUVÉDERM VOLUX XC represents the largest leap in innovation for our U.S. HA portfolio since the introducti…
- Zoryve from Arcutis Approved for Plaque Psoriasishttps://practicaldermatology.com/news/zoryve-from-arcutis-approved-for-plaque-psoriasis/2461282/FDA has approved the New Drug Application (NDA) for Zoryve (roflumilast) cream 0.3% from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The first and only topical phosphodiesterase-4 (PDE4) inhibitor approved fo…
- Incyte's Opzelura Adds Vitiligo Indicationhttps://practicaldermatology.com/news/incytes-opzelura-adds-vitiligo-indication/2461274/Opzelura™ (ruxolitinib) cream 1.5% from Incyte is now approved for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Opzelura is the first and only FDA-approved treatment for repigmentation in patients with vitiligo and the only topical formul…
- FDA Approves Olumiant from Eli Lilly for Alopecia Areatahttps://practicaldermatology.com/news/fda-approves-olumiant-from-eli-lilly-for-alopecia-areata/2461231/Olumiant (baricitinib) from Eli Lilly and Company is approved to treat adult patients with severe alopecia areata. FDA action marks the first approval of a systemic treatment for alopecia areata. Olumiant is a Janus kinase (JAK) inhibitor. The efficacy and safety of olumiant in alopecia areata was…
- FDA Approves Dermavant's Vtama for Psoriasishttps://practicaldermatology.com/news/fda-approves-dermavants-vtama-for-psoriasis/2461205/FDA has approved Vtama® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist from Dermavant for the topical treatment of plaque psoriasis in adults. Vtama cream is the first and only FDA-approved steroid-free topical medication in its class. Dermavant says it will have product available in…
- Third Harmonic Bio Launches with an Eye on Chronic Urticariahttps://practicaldermatology.com/news/third-harmonic-bio-launches-with-an-eye-on-chronic-urticaria/2461078/Third Harmonic Bio is launching with the close of a Series B financing campaign. With total capital to date of $155 million, the company plans to fund development of its lead candidate, THB001, through the next phase of human studies for the initial indication of chronic urticaria. Atlas Venture …
- FDA Approves New Cheek Filler from Galdermahttps://practicaldermatology.com/news/fda-approves-new-cheek-filler-from-galderma/2460856/The U.S. Food and Drug Administration (FDA) approved Galderma’s Restylane Contour for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. Restylane Contour, a new hyaluronic acid (HA) dermal filler, is Galderma's first and only product in the U.S. formul…
- OMNY Health Launches Integrated Dermatology Data Repository and Research Networkhttps://practicaldermatology.com/news/omny-health-launches-integrated-dermatology-data-repository-and-research-network/2460845/OMNY Health has partnered with community-based dermatology practices to create a first-of-a-kind integrated, normalized, de-identified electronic health record (EHR) data repository for dermatological research. The assembled longitudinal data represents care delivered over the past five years by …
- Breaking Business News: Revance to Acquire HintMDhttps://practicaldermatology.com/news/breaking-business-news-revance-to-aquire-hintmd/2460399/Revance Therapeutics, Inc. has acquired HintMD, a financial technology platform for the aesthetics industry. Revance has agreed to pay HintMD’s shareholders a total of 8.54 million shares of Revance common stock, subject to customary adjustments provided in the acquisition agreement. The transacti…